[Interleukin 2].
Effectiveness of IL-2 and LAK cells induced by IL-2 on malignant diseases was discussed. IL-2 alone administered systemically showed a poor effect, and combination of IL-2 are necessary for LAK cells to kill the target malignant cells. Adoptive immunotherapy using IL-2 and LAK cells should be applied for pulmonary and hepatic metastases. Postoperative adjuvant therapy and combination with chemotherapy will become important in the future.
D006801:Humans; D007116:Immunization, Passive; D007376:Interleukin-2 / Q000008:administration & dosage / Q000627:therapeutic use*; D007694:Killer Cells, Natural / Q000276:immunology; D008175:Lung Neoplasms / Q000628:therapy; D008223:Lymphoma / Q000628:therapy; D009369:Neoplasms / Q000628:therapy*; D012878:Skin Neoplasms / Q000628:therapy; D013274:Stomach Neoplasms / Q000628:therapy
D007376:Interleukin-2